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1. Introduction 
Gastric carcinoma has been considered an aetiologically heterogeneous entity, with the role 
of its potential determinants differing with tumour location (Cavaleiro-Pinto et al., 2011; 
Helicobacter and Cancer Collaborative Group, 2001; Huang et al., 1998; Huang et al., 2003; 
Ladeiras-Lopes et al., 2008; Larsson et al., 2006; Lunet et al., 2007; Tredaniel et al., 1997; 
World Cancer Research Fund & American Institute for Cancer Research, 2007) and 
histological type (Helicobacter and Cancer Collaborative Group, 2001; Huang et al., 1998; 
Ladeiras-Lopes et al., 2008; Larsson et al., 2006; Lunet et al., 2007; World Cancer Research 
Fund & American Institute for Cancer Research, 2007). Regarding the latter, Laurén 
proposed an histo-clinical classification (Laurén, 1965) comprising two main histological 
types – diffuse and intestinal – with different frequency and distribution across populations 
(Muñoz & Asvall, 1971; Muñoz & Connelly, 1971). Most gastric carcinomas belong to the 
intestinal type, representing between 52% and 82% of all gastric cancers (Kaneko & 
Yoshimura, 2001; Laurén & Nevalainen, 1993; Wu et al., 2009). A higher incidence of 
intestinal type tumours was observed in males, blacks and older subjects, while the diffuse 
type had a similar incidence in both genders and was more frequent in younger individuals 
(Correa et al., 1973; Ekström et al., 2000). Also, there was a wide geographical variation in 
the frequency of intestinal type tumours, whereas the occurrence of diffuse 
adenocarcinomas was more uniform across regions (Laurén & Nevalainen, 1993). In 
addition, the decrease in cancer incidence among migrants from high- to low-risk areas was 
observed predominantly for tumours of the intestinal type (Correa et al., 1973). These 
findings were taken as evidence of a relatively greater impact of environmental factors in 
the aetiology of intestinal type carcinomas, while the diffuse type was considered more 
dependent on the genetic profile of the individuals (Tahara, 2004). Pelayo Correa (Correa et 
al., 1975) proposed a model for the development of the intestinal type tumours, according to 
which the precancerous lesions occur in sequential steps: chronic atrophic gastritis, 
intestinal metaplasia, and dysplasia. It provided a framework for understanding the role of 
different environmental and constitutional factors in gastric carcinogenesis, which has 
evolved with the epidemiologic findings on this topic. 
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2. Gastric carcinogenesis models 
In his initial model (Correa et al., 1975), Correa postulated that both deleterious and 
protective exposures could modulate the progression towards intestinal type cancers, by 
acting in different stages of the pathway. With the rediscovery of Helicobacter pylori in 1984 
(Marshall & Warren, 1984) and the gradual recognition of its role as a carcinogen, the model 
was redefined to accommodate the causal relation between H. pylori infection and gastric 
cancer (Correa, 1992), assuming that its effects were exerted at the early phases of gastric 
carcinogenesis (Figure 1). 
 
 
 
 
 
+ positive associations (increase the risk of gastric cancer); – negative associations (decrease the risk of 
gastric cancer). 
Fig. 1. Gastric carcinogenesis model for the carcinomas of Laurén intestinal type, according 
to the proposed by Pelayo Correa (Correa, 1992) 
The models proposed by Pelayo Correa more than 15 years ago still provide the essential 
framework for research on gastric carcinogenesis. The understanding of potentially 
alternative pathways, the more accurate definition of the endpoints for research, and the 
identification of the carcinogenesis steps where each of the gastric cancer causal components 
may act will contribute for a better understanding of cancer aetiology and support the 
development of preventive strategies. 
2.1 The effect of risk factors for gastric cancer across the carcinogenesis pathway 
The research on the determinants of gastric cancer precursors has been less extensive than 
for the cancer endpoints. In Table 1 we present a summary of the systematic reviews and 
meta-analyses of research conducted to assess the determinants of the lesions that precede 
the cancer. The contribution of these findings for improvement of the currently  
accepted gastric carcinogenesis model will be discussed in the following sections of this 
chapter. 
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Author, year 
(ref) 
Exposure Outcome 
Databases
searched 
Number 
of studies
included 
Main results 
Adamu, 2010 
(Adamu et 
al., 2010) 
H. pylori
infection 
CAG 
incidence 
MEDLINE,
EMBASE 
14 H. pylori-infected vs. 
uninfected 
RR=5.0 (95%CI: 3.1-8.3) 
 
Includes studies with follow-
up periods ranging from 5 to 
32 years
Peleteiro, 
2010 
(Peleteiro et 
al., 2010b) 
IL1RN
VNTR 
IL1B-511 
TNFA-308
CAG 
prevalence
IM 
prevalence
PubMed 15 IL1RN VNTR (22 vs. LL) 
CAG and IM: 
OR=2.27 (95%CI: 1.40-3.70) 
CAG: 
OR=1.65 (95%CI: 1.02-2.66) 
IM: 
OR=2.27 (95%CI: 1.14-4.51) 
 
IL1B-511 (TT vs. CC) 
CAG and IM: 
OR=1.34 (95%CI: 0.87-2.07) 
CAG: 
OR=1.20 (95%CI: 0.70-2.05) 
IM: 
OR=1.94 (95%CI: 1.14-3.31) 
 
TNFA-308 (AA vs. GG) 
CAG and IM: 
OR=0.93 (95%CI: 0.35-2.43) 
Dias-Neto, 
2010 
(Dias-Neto et 
al., 2010) 
Salt 
intake 
IM 
prevalence
PubMed 17 Salted/salty meat intake 
(highest vs. lowest exposure) 
OR=1.68 (95%CI: 0.98-2.90) 
 
Preference for salted/salty 
foods or use of table salt 
(highest vs. lowest exposure) 
OR=1.53 (95%CI: 0.72-3.24) 
Weck, 2008 
(Weck & 
Brenner, 
2008) 
H. pylori
infection
CAG 
prevalence 
evaluated 
by: 
- 
gastroscopy 
with 
biopsy 
- PG I only
- PG I/PG 
II ratio
MEDLINE 66 H. pylori-infected vs. 
uninfected 
Gastroscopy with biopsy: 
OR=6.4 (95%CI: 4.0-10.1) 
PG I only *: 
OR=0.9 (95%CI: 0.7-1.2) 
PG I/PG II ratio: 
OR=7.2 (95%CI: 3.1-16.8) 
Combination of PG I and PG 
I/PG II ratio: 
OR=5.7 (95%CI: 4.4-7.4) 
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Author, year 
(ref) 
Exposure Outcome 
Databases
searched 
Number 
of studies
included 
Main results 
- combi-
nation of 
PG I and 
PG I/PG II 
ratio
All methods:
OR=4.7 (95%CI: 3.7-6.0) 
All methods, except PG I 
only: 
OR=6.1 (95%CI: 4.8-7.7) 
Peleteiro, 
2008 
(Peleteiro et 
al., 2008) 
H. pylori
infection
Smoking
IM 
prevalence
PubMed 22 Systematic review for 
identification of estimates 
for IM prevalence among H. 
pylori-infected subjects in 
different populations and 
ecological analysis of the 
association with smoking 
 
Pearson correlation 
coefficient = 0.45 (p=0.02) 
Rokkas, 2007 
(Rokkas et 
al., 2007) 
H. pylori
eradica-
tion 
CAG 
incidence 
IM 
incidence 
MEDLINE 8 H. pylori-eradicated vs. 
placebo 
CAG in the antrum: 
OR=0.554 (95%CI: 0.372-
0.825) 
CAG in the corpus: 
OR=0.209 (95%CI: 0.081-
0.538) 
IM in the antrum: 
OR=0.795 (95%CI: 0.587-
1.078) 
IM in the corpus: 
OR=0.891 (95%CI: 0.633-
1.253) 
 
Includes studies with 
follow-up periods ranging 
from 10 to 137 months 
CAG – chronic atrophic gastritis; RR – relative risk; VNTR – variable number tandem repeat; IM – 
intestinal metaplasia; OR – odds ratio; PG – pepsinogen. 
* the magnitude of the association depends on the method used to assess atrophy; previous studies showed 
that PG I alone had a low sensitivity for serological definition of chronic atrophic gastritis (Miki, 2006). 
† systematic reviews and meta-analyses were identified through PubMed search, from its inception to 
December 2010, under the following expression (gastritis OR chronic OR atroph* OR intestinal metaplasia 
OR dysplasia) AND (gastric OR stomach) AND (helicobacter pylori OR gene OR polymorphism OR SNPs OR 
smoking OR tobacco OR cigarette OR salt OR antioxidant OR diet OR lifestyle OR environmental OR 
behaviour) AND (meta-analysis OR "systematic review"). 
Table 1. Summary of systematic reviews and meta-analyses † addressing the role of genetic 
and environmental factors on the occurrence of gastric precancerous lesions 
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2.1.1 The role of Helicobacter pylori infection 
The association between H. pylori infection and gastric cancer is well established, with several 
meta-analyses reporting an odds ratio of approximately 2 (Figure 2). The prevalence of H. 
pylori infection is high (74% in developing and 58% in developed countries, on average) and 
nearly two-thirds of all gastric cancers occurring worldwide are attributed to it (Parkin, 2006). 
Pelayo Correa proposed that H. pylori infection acted at the early phases of the 
carcinogenesis based on the fact that the inflammatory reaction could disappear after 
clearance of the bacteria with antibiotic treatment (Correa, 1992), and this has received 
support from several lines of evidence. On the one hand, the longer the lag between the 
assessment of H. pylori infection status and the diagnosis of gastric cancer, the stronger is the 
association between infection and cancer (Helicobacter and Cancer Collaborative Group, 
2001; Huang et al., 1998), as H. pylori clearance tends to occur with the progression to the 
cancer endpoint (Gao et al., 2009; Kokkola et al., 2003). Case-control designs tend to 
underestimate the relation between infection and gastric cancer, but studies that used more 
sensitive methods to detect past infection or restricted the analysis to less advanced cases 
yielded stronger relative risk estimates (Brenner et al., 2004; Ekstrom et al., 2001; Mitchell et 
al., 2008; Peleteiro et al., 2010a). On the other hand, this is also in accordance with the 
stronger associations observed between H. pylori and precancerous lesions (Table 1) than 
with gastric cancer, as depicted in Figure 2. 
 
 
Fig. 2. Meta-analyses on the association between Helicobacter pylori infection and chronic 
atrophic gastritis, and gastric cancer (Adamu et al., 2010; Cavaleiro-Pinto et al., 2011; 
Danesh, 1999; Eslick et al., 1999; Helicobacter and Cancer Collaborative Group, 2001; Huang 
et al., 1998; Weck & Brenner, 2008; Xue et al., 2001). 
.
.
Chronic atrophic gastritis
Weck & Brenner, 2008 (prevalence)
Adamu et al., 2010 (incidence)
Gastric cancer
Huang et al., 1998
Huang et al., 1998 (cohort)
Huang et al., 1998 (case-control)
Huang et al., 1998 (intestinal type)
Huang et al., 1998 (diffuse type)
Danesh, 1999 (nested case-control)
Eslick et al., 1999 
HCCG, 2001 (nested case-control)
Xue et al., 2001 
Cavaleiro-Pinto et al., 2011 (noncardia)
ID
Study
6.10 (4.80, 7.70) 
5.00 (3.10, 8.30) 
1.92 (1.32, 2.78) 
2.24 (1.15, 4.40) 
1.81 (1.16, 2.84) 
2.49 (1.41, 4.43) 
2.58 (1.47, 4.53) 
2.50 (1.90, 3.40) 
2.04 (1.69, 2.45) 
2.36 (1.98, 2.81) 
3.00 (2.42, 3.72) 
2.81 (2.14, 3.68) 
RR (95% CI)
  1.5 2 5 10
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A direct correlation between H. pylori prevalence and gastric cancer rates is not observed 
when countries with different patterns of infection and gastric cancer risk are considered, 
namely because some of them present low gastric cancer incidences despite the high 
prevalences of infection, the so-called African and Asian enigmas (Holcombe, 1992; Miwa et 
al., 2002). In the latter settings, the cancer precursor lesions, especially intestinal metaplasia, 
are also less frequent than expected given the high prevalence of infection (Campbell et al., 
2001; Carrilho et al., 2009; Kalebi et al., 2007; Kidd et al., 1999; Oluwasola & Ogunbiyi, 2004), 
supporting the hypothesis that H. pylori infection acts before their development (in earlier 
steps of the carcinogenesis) and that other genetic and/or environmental exposures 
modulate the progression towards cancer (Campbell et al., 2001; Louw et al., 2001; Lunet & 
Barros, 2003; Mitchell et al., 2002). 
2.1.1.1 The impact of Helicobacter pylori eradication 
Since the recognition of the causal link between H. pylori and gastric cancer, research has 
focused on the potential of eradication of the infection as preventive tool. Some clinical trials 
concluded that H. pylori eradication reduces gastric cancer risk (Fuccio et al., 2009; Ito et al., 
2009) (Figure 3). However, one of the trials (Wong et al., 2004) analysed separately the 
subjects with and without precancerous lesions, and eradication of H. pylori infection was 
significantly associated with a decreased risk of developing gastric cancer only among the   
 
 
* this report refers to a systematic review but does not include a meta-analysis, and summary estimates 
were computed by the authors of this chapter based on the results presented for each individual study. 
Fig. 3. Meta-analyses on the association between Helicobacter pylori eradication and incidence 
of chronic atrophic gastritis, intestinal metaplasia, and gastric cancer (Fuccio et al., 2009; Ito 
et al., 2009; Rokkas et al., 2007). 
. 
. 
. 
Chronic atrophic gastritis
Rokkas et al., 2007 (antrum)
Rokkas et al., 2007 (corpus)
Intestinal metaplasia
Rokkas et al., 2007 (antrum)
Rokkas et al., 2007 (corpus)
Gastric cancer
Fuccio et al., 2009 (randomized controlled trials)
Ito et al., 2009 (randomized controlled trials) *
Ito et al., 2009 (non-randomized studies) *
I
Study
0.55 (0.37, 0.82)
0.21 (0.08, 0.54)
0.80 (0.59, 1.08)
0.89 (0.66, 1.25)
0.65 (0.43, 0.98)
0.58 (0.39, 0.84)
0.32 (0.21, 0.49)
RR (95% CI)
  1.1 .2 .5 1.5
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latter, supporting the hypothesis of the effects of infection in the early stages of gastric 
carcinogenesis. This is also in accordance with the lack of association between eradication 
and cancer in a trial conducted in Colombia, which only included subjects with gastric 
precancerous lesions at baseline evaluation (Correa et al., 2000; Mera et al., 2005). 
Also, a meta-analysis from Rokkas et al. (Rokkas et al., 2007) estimated the long-term impact 
of H. pylori eradication on the incidence of gastric precancerous lesions (Table 1), with 
significant reduction in chronic atrophic gastritis risk but not for intestinal metaplasia 
(Figure 3). 
Taken together, these results support the irreversibility of intestinal metaplasia, since H. 
pylori eradication must occur before a point of no return in order to be effective. This 
represents one more piece of evidence of an early role for H. pylori infection in the gastric 
carcinogenesis, as it leads to intestinal metaplasia but must be complemented with other 
factors for progression towards cancer. 
2.1.2 The role of lifestyle factors 
Although H. pylori infection is the most important gastric cancer determinant, only a small 
proportion of infected subjects will reach this endpoint (Hsu et al., 2007; Uemura et al., 
2001), and several other potential causal components have to be considered. 
2.1.2.1 Smoking 
Stomach cancer is now considered a tobacco-related cancer, with 17% of cases among men 
and 11% among women being attributed to it in the more developed countries (IARC 
Working Group on the Evaluation of Carcinogenic Risks to Humans, 2004). Compared to 
never-smokers, current smokers have a 20% (among women) to 62% (among men) higher 
risk of gastric cancer, while gastric cancer is 16% (among women) to 34% (among men) more 
frequent in former smokers (Ladeiras-Lopes et al., 2008). This shows that the interruption of 
the exposure to tobacco contributes to a reduction in gastric cancer risk, supporting that its 
effects are exerted at the later steps of carcinogenesis. Furthermore, the risk of cancer was 
higher in subjects quitting smoking more recently (summary RR for studies with a 
mean/median follow-up time < 10 vs. ≥ 10 years: 1.39, 95%CI: 1.30-1.49 vs. 1.09, 95%CI: 0.95-
1.25, among men) (Ladeiras-Lopes et al., 2008), in accordance with the hypothesis that 
smoking acts predominantly by promoting the progression from the more advanced 
precursor lesions to cancer. 
Among lifestyle exposures, the relation between smoking and precancerous lesions, 
especially intestinal metaplasia, has been the more extensively studied, but no systematic 
reviews of studies quantifying this association are available. The individual reports that 
have been published yielded relative risk estimates ranging from 1.42 to 4.91 (Kim et al., 
2008; Mesquita et al., 2006). An ecological analysis showed a strong correlation between 
apparent tobacco consumption and the frequency of intestinal metaplasia among H. pylori-
infected subjects (Peleteiro et al., 2008), suggesting that the low cigarette consumption 
observed in developing countries may be a contributory factor for the disruption of the 
carcinogenesis pathway, precluding the progression to the more advanced lesions. This was 
also supported by another ecological analysis that showed lower gastric cancer incidence 
rates in settings with high prevalence of infection and low apparent tobacco consumption 
than in those where smoking was more frequent (Lunet & Barros, 2003). 
Taken together, these results are indicative of a role for smoking in the stages closer to 
cancer. 
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2.1.2.2 Salt 
The proposed mechanisms by which salt can cause gastric cancer are either the direct 
damage of the gastric mucosa causing excessive cell replication or an indirect effect by 
increasing of the mutagenic potential of N-nitroso compounds, which is compatible with the 
action of salt intake at the initial and late stages of gastric carcinogenesis, respectively 
(Correa, 1992). More recently, it was shown that the damage caused by salt may also 
increase gastric H. pylori colonization (Fox et al., 1999; Nozaki et al., 2002), which is also 
supportive of an early role in the pathway. 
Many methodological limitations preclude valid measurements of salt consumption (Chen 
et al., 1990), and the excretion of sodium in urine over a 24-h period is the method that 
reflects more accurately the sodium ingested from different sources (World Cancer Research 
Fund & American Institute for Cancer Research, 2007). The latter, however, was used only 
in an ecological study assessing the association between salt and intestinal metaplasia (ECP-
EURONUT, 1994). 
The summary estimates for the relation between total salt use and gastric cancer obtained in 
the World Cancer Research Fund meta-analysis correspond to a relative risk of 
approximately 2 (Figure 4). However, only 17 of the 71 studies identified trough systematic 
review were included in the meta-analysis, due to the large heterogeneity in the 
presentation of results (World Cancer Research Fund & American Institute for Cancer 
Research, 2007). 
 
 
Fig. 4. Meta-analyses on the association between salt intake and intestinal metaplasia, and 
gastric cancer (Dias-Neto et al., 2010; World Cancer Research Fund & American Institute for 
Cancer Research, 2007). 
. 
. 
Intestinal metaplasia
Dias-Neto et al., 2010 (salted/salty meat)
Dias-Neto et al., 2010 (salt preference)
Gastric cancer
WCRF, 2007 (total salt use)
ID 
Study
1.68 (0.98, 2.90)
1.53 (0.72, 3.24)
1.90 (1.59, 2.27)
RR (95% CI)
  1.5 2 5
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In the meta-analysis conducted by Dias-Neto et al. (Dias-Neto et al., 2010), salted/salty meat 
intake and preference for salted/salty foods or use of table salt were associated with an 
approximately 60% increased risk of intestinal metaplasia (Figure 4), but the authors 
concluded that the large methodological heterogeneity and in the presentation of the results 
did not allow a more comprehensive quantitative synthesis or a conclusive overall 
interpretation of the findings. 
The evidence currently available on this topic precludes definite conclusions on the 
magnitude of the effects of salt consumption, overall and in different steps of carcinogenesis. 
2.1.2.3 Antioxidants 
Based on the inverse association between ingestion of fresh fruits and vegetables and gastric 
cancer observed in epidemiological studies, antioxidants such as ascorbic acid and beta-
carotene were postulated to play a protective role in the stages closer to cancer by acting as 
free-radical scavengers (Correa, 1992). This protective effect of fruits and vegetables, 
however, seems to be weaker than initially expected. The summary estimates from several 
meta-analyses on this topic are closer to 1 when derived from cohort studies, ranging from 
0.89 to 0.95 for fruits intake and from 0.89 to 0.98 for vegetables consumption (Figure 5).  
 
 
Fig. 5. Meta-analyses on the association between fruits and vegetables intake and gastric 
cancer (Lunet et al., 2005; Lunet et al., 2007; Riboli & Norat, 2003; World Cancer Research 
Fund & American Institute for Cancer Research, 2007). 
. 
. 
Fruits intake 
Riboli & Norat, 2003
Riboli & Norat, 2003 (cohort)
Riboli & Norat, 2003 (case-control)
Lunet et al., 2005 (cohort)
WCRF, 2007 (cohort)
WCRF, 2007 (case-control)
Lunet et al., 2007 (intestinal type)
Lunet et al., 2007 (diffuse type)
Vegetables intake
Riboli & Norat, 2003
Riboli & Norat, 2003 (cohort)
Riboli & Norat, 2003 (case-control)
Lunet et al., 2005 (cohort)
WCRF, 2007 (cohort)
WCRF, 2007 (case-control)
Lunet et al., 2007 (intestinal type)
Lunet et al., 2007 (diffuse type)
ID
Study
0.74 (0.69, 0.81)
0.89 (0.73, 1.09)
0.69 (0.62, 0.77)
0.89 (0.78, 1.02)
0.95 (0.89, 1.02)
0.67 (0.59, 0.76)
0.49 (0.33, 0.72)
0.82 (0.57, 1.20)
0.81 (0.75, 0.87)
0.89 (0.75, 1.05)
0.78 (0.71, 0.86)
0.98 (0.86, 1.13)
0.98 (0.91, 1.06)
0.70 (0.62, 0.79)
0.61 (0.44, 0.86)
0.67 (0.44, 1.01)
RR (95% CI) 
  1.2 .5 2
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However, a stronger protective effect was observed in studies with a follow-up of 10 or 
more years (OR=0.66, 95%CI: 0.52-0.83 for fruits and OR=0.71, 95%CI: 0.53-0.94 for 
vegetables in incidence studies) (Lunet et al., 2005), which may be seen as evidence of a 
relatively early effect of these factors in the gastric carcinogenesis pathway. Research on this 
topic having cancer precursor lesions as the outcome has seldom been conducted, with few 
studies reporting conflicting results regarding chronic atrophic gastritis and intestinal 
metaplasia (Jedrychowski et al., 1999; Kato et al., 2004; Kuwahara et al., 2000; Sierra et al., 
2008). 
Chemoprevention trials have found no evidence of a beneficial effect for antioxidant 
supplementation on gastric cancer prevention (Bjelakovic et al., 2004; Druesne-Pecollo et al., 
2010). 
Although it is plausible that naturally occurring antioxidants may inhibit the carcinogenesis 
progression, there is limited evidence on the specific steps where these factors may act. 
2.1.2.4 N-nitroso compounds 
N-nitroso compounds were hypothesized to act in gastric carcinogenesis by promoting the 
synthesis of carcinogens via nitrosation reactions (Correa, 1992). Processed meat is often an 
important source of exposure to carcinogenic N-nitroso compounds, and a meta-analysis of 
studies that quantified the association between processed meat consumption and stomach 
cancer found stronger associations for case-control studies (case-control vs. cohort: OR=1.63, 
95%CI: 1.31-2.01 vs. OR=1.24, 95%CI: 0.98-1.56) (Larsson et al., 2006). The relation between 
these exposures and cancer precursor lesions has seldom been addressed (Sobala et al., 1991; 
You et al., 1996) and the effect of these compounds in the gastric carcinogenesis pathway 
remains to be fully understood. 
2.1.3 The role of genetic factors 
The genetic profile of the individuals was not included in the first versions of the model 
proposed by Correa (Correa, 1992; Correa et al., 1975) but, along with the advent of new 
technologies and their use in epidemiological research, several studies addressing the 
association between genetic polymorphisms and gastric cancer have been conducted. In the 
aetiological model of gastric cancer, individual genetic susceptibility may be critical in a 
variety of processes relevant to gastric carcinogenesis, namely mucosal protection, 
inflammatory response, carcinogen detoxification, antioxidant protection, DNA repair and 
oncogenes and tumour suppressor genes expression. The most widely studied 
polymorphisms, and for which more promising results have been achieved, are those 
related to proinflammatory cytokines, namely within interleukin-1 (IL1) and tumour 
necrosis factor ǂ (TNFA) gene clusters. 
2.1.3.1 Cytokine gene polymorphisms 
H. pylori infection induces both interleukin-1ǃ (IL-1ǃ) and tumour necrosis factor-ǂ (TNF-ǂ) 
production, and these cytokines inhibit gastric acid secretion, leading to the development of 
gastric precancerous lesions and cancer (El-Omar et al., 2000; Hwang et al., 2002). The IL1B 
gene codes for the IL-1ǃ and the IL1RN gene for an anti-inflammatory cytokine, interleukin-
1 receptor antagonist (IL-1ra). Polymorphisms within the IL1B gene increase IL-1ǃ 
expression and IL-1ra binds to the IL-1 receptors, modulating the pro-inflammatory effects 
of IL-1ǃ. Regarding the IL1RN gene, a variable number tandem repeat (VNTR) 
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polymorphism has been detected within intron 2, and five allelic variants have been 
identified in the number of repeats varying from 2 to 6 (El-Omar, 2001; Gonzalez et al., 
2002). The ability of H. pylori to infect and remain in the human stomach induces a chronic 
inflammatory response, which may be of variable magnitude depending on the genetic 
make-up of the host. Most of the single nucleotide polymorphisms (SNPs) studied are 
situated in the gene promoter region and play important roles in modulating gene 
expression and thus the inflammatory response. 
Previous meta-analyses have shown an increased gastric cancer risk associated with 
polymorphisms in IL1RN, IL1B-511 and TNFA-308 (Figure 6). The IL1RN*22 genotype 
increases the risk of gastric precancerous lesions, suggesting a role for this polymorphism in 
the early stages of gastric carcinogenesis, while positive associations between IL1B-511 TT 
genotype and gastric precancerous lesions only became apparent when studies addressing 
intestinal metaplasia as the outcome were considered (Figure 6). These associations were  
 
 
 
 
 
 
 
Fig. 6. Meta-analyses on the association between cytokine gene polymorphisms and chronic 
atrophic gastritis, intestinal metaplasia, and gastric cancer (Camargo et al., 2006; Gorouhi et 
al., 2008; Kamangar et al., 2006; Loh et al., 2009; Peleteiro et al., 2010b; Vincenzi et al., 2008; 
Wang et al., 2007). 
. 
. 
. 
IL1RN 
Peleteiro et al., 2010 (chronic atrophic gastritis)
Peleteiro et al., 2010 (intestinal metaplasia)
Camargo et al., 2006 (gastric cancer)
Kamangar et al., 2006 (gastric cancer)
Wang et al., 2007 (gastric cancer)
Loh et al., 2009 (gastric cancer)
IL1B-511 
Peleteiro et al., 2010 (chronic atrophic gastritis)
Peleteiro et al., 2010 (intestinal metaplasia)
Camargo et al., 2006 (gastric cancer)
Kamangar et al., 2006 (gastric cancer)
Wang et al., 2007 (gastric cancer)
Vincenzi et al., 2008 (gastric cancer)
Loh et al., 2009 (gastric cancer)
TNFA-308 
Peleteiro et al., 2010 (chronic atrophic gastritis/intestinal metaplasia)
Gorouhi et al., 2008 (gastric cancer)
Loh et al., 2009 (gastric cancer)
ID 
Study 
1.65 (1.02, 2.66)
2.27 (1.14, 4.51)
1.17 (1.00, 1.37)
1.23 (0.79, 1.92)
1.20 (1.02, 1.42)
1.19 (1.09, 1.30)
1.20 (0.70, 2.05)
1.94 (1.14, 3.31)
1.21 (1.00, 1.47)
1.16 (0.95, 1.42)
1.26 (1.03, 1.55)
1.23 (1.09, 1.37)
1.10 (1.02, 1.18)
0.93 (0.35, 2.43)
1.49 (1.11, 1.99)
1.19 (1.06, 1.32)
RR (95% CI)
  1.2 .5 2 5
www.intechopen.com
 
Gastritis and Gastric Cancer – New Insights in Gastroprotection, Diagnosis and Treatments 
 
208 
stronger among studies conducted in samples with high H. pylori prevalence, in accordance 
to what is known about the gene function and its potential interaction with infection. No 
overall association was found for TNFA-308 AA genotype (Figure 6). 
2.2 Other markers of gastric cancer development 
The currently available evidence shows no substantial aetiological differences between the 
main Laurén subtypes, despite the relatively small number of studies addressing the effect 
of environmental exposures on the risk of gastric cancer according to histological subtypes 
(Figures 2 and 5). This may partially reflect misclassification of the histological type, due to 
inter-observer variability, the type of specimen available for diagnosis, and the proportion 
of tumours classified as unknown (Carneiro et al., 2007). 
An additional concern is the ability for the classification proposed by Laurén to define 
aetiologically homogeneous subgroups of gastric cancer cases. The cascade of events that 
involve intestinal differentiation is mediated by CDX1 and/or CDX2 (Guo et al., 2004), and 
may result in the development of both intestinal and diffuse gastric carcinoma (Almeida et 
al., 2003). In particular, CDX2 expression is regarded as a marker of the intestinal epithelial 
phenotype, and the transdifferentiation of normal epithelia has been experimentally 
induced by changes in local environment (Marchetti et al., 2003), which supports the 
hypothesis that environmental exposures may modulate the CDX2 expression. This may be 
seen as an early marker of intestinal differentiation, that may be used as an endpoint 
occurring in the gastric carcinogenesis pathway even earlier than chronic atrophic gastritis 
or intestinal metaplasia. Research relying on these tools to define the outcomes is still scarce 
(Yuasa et al., 2009; Yuasa et al., 2005), but may be important to understand the aetiological 
heterogeneity of gastric cancer. 
Histopathological and histochemical studies allowed the identification of two main types of 
intestinal metaplasia. The complete, also designated type I, and the incomplete, comprising 
types II and III (Filipe & Jass, 1986). In the classical multistep model of the gastric 
precancerous process, incomplete follows complete intestinal metaplasia sequentially 
(Correa, 1992). However, according to the patterns of mucin expression observed within 
each intestinal metaplasia type, it has been hypothesised that the complete and incomplete 
types of intestinal metaplasia may represent two alternative pathways, rather than 
successive steps; or that type II may represent a first step in the pathway, which may evolve 
to type I or to type III (Reis et al., 1999). The evaluation of specific risk factors for these 
endpoints may clarify the gastric carcinogenesis pathways and the role of environmental 
exposures in the aetiology of cancer (Peleteiro et al., 2007; Pintalhao et al., 2010). 
3. Conclusion 
The accumulated evidence so far led to the gradual acceptance and better understanding of 
the role of H. pylori infection and smoking in gastric carcinogenesis. For other exposures, 
however, there is much less robust evidence on the magnitude of the associations or their 
role throughout carcinogenesis. This allows an update of the model proposed by Correa, 
that still provides the best framework for gastric cancer etiological research, taking into 
account the evidence generated in the last two decades (Figure 7). 
Research relying on more accurate tools to define specific gastric cancer subtypes and the 
evaluation of specific risk factors for early endpoints in the gastric carcinogenesis pathway 
may further contribute to the understanding of gastric cancer aetiology. 
www.intechopen.com
 
Role of Genetic and Environmental Risk Factors in Gastric Carcinogenesis Pathway  
 
209 
 
Fig. 7. Framework for the carcinogenesis pathway leading to gastric cancer, taking into 
account the model proposed by Correa (Correa, 1992) and the more robust evidence 
gathered up to 2010. 
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